SCHEMBL3528065

SCHEMBL3528065

Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccc(NC(=O)CCN6CCCCC6)c5)cnc(N)c34)cc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.70
AURKB Q96GD4 10/20 0.70
AURKA O14965 6/20 0.69
ALK Q9UM73 3/20 0.69
KIT P10721 6/20 0.68
CSF1R P07333 5/20 0.68
FLT1 P17948 5/20 0.68
FLT3 P36888 5/20 0.68
NEK2 P51955 5/20 0.68
PLK4 O00444 4/20 0.68
ROCK2 O75116 4/20 0.68
INSR P06213 4/20 0.68
LCK P06239 4/20 0.68
FYN P06241 4/20 0.68
LYN P07948 4/20 0.68
MET P08581 4/20 0.68
FGFR1 P11362 4/20 0.68
SRC P12931 4/20 0.68
FGFR3 P22607 4/20 0.68
RPS6KB1 P23443 4/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530203 0.98 AURKA (0.72) KDRAURKBAURKAALKKIT
SCHEMBL27904958 0.91 KDR (0.63) KDRAURKBAURKAALKKIT
SCHEMBL27922895 0.88 KDR (0.65) KDRAURKBAURKAALKKIT
SCHEMBL3569514 0.87 KDR (0.73) KDRAURKBAURKAALKKIT
SCHEMBL3533672 0.86 KDR (0.74) KDRAURKBAURKAALKKIT
SCHEMBL3532466 0.86 AURKA (0.87) KDRAURKBAURKAALKKIT
SCHEMBL3530382 0.85 KDR (0.93) KDRAURKBAURKAALKKIT
SCHEMBL3532689 0.84 AURKA (0.95) KDRAURKBAURKAALKKIT
SCHEMBL3534124 0.84 AURKA (0.79) KDRAURKBAURKAALKKIT
SCHEMBL3581493 0.84 KDR (0.86) KDRAURKBAURKAALKKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885AURKA 207/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885AURKA 207/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885AURKA 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.